Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Belgium / NCT04032470
Recruiting Observational

Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)

NCT04032470 · tracked via the Priya Life Science Belgium tracker
Phase
Observational
Started
2019-10-23
Last updated
2026-09-11

Condition(s) studied

Essential Tremor

Investigational drug(s) / intervention(s)

Deep Brain Stimulation Systems (DBS)

Deep Brain Stimulation Systems (DBS): Subjects receiving DBS implant for treatment of Essential Tremor

Study summary

To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of Essential Tremor.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Meets criteria established in the locally applicable Directions for Use (DFU) for Essential Tremor * Is at least 18 years old Exclusion Criteria: * Meets any contraindication in locally applicable Directions for Use

Primary outcome measure(s)

Trial sites (20)

FacilityCityRegionStatus
A.o. LKH Univ.-Kliniken Innsbruck Innsbruck Austria Recruiting
AZ Sint-Lucas Ghent Belgium Recruiting
UZ Gasthuisberg Leuven Belgium Recruiting
AZ Delta Roeselare Belgium Recruiting
Vancouver General Hospital Vancouver Canada Recruiting
Uniklinik Koln Cologne Germany Recruiting
Universitaetsklinikum Dusseldorf Düsseldorf Germany Recruiting
Universitaetsklinikum Essen Essen Germany Recruiting
Universitatsklinikum Campus Kiel Kiel Germany Recruiting
Universitaetsklinikum Giessen und Marburg GmbH Marburg Germany Recruiting
Evangelisches Krankenhaus Oldenburg Oldenburg Germany Recruiting
Universitaetsklinikum Wuerzburg Würzburg Germany Recruiting
Medical School of University PECS Pécs Hungary Recruiting
Policlinico Universitario Agostino Gemelli Rome Italy Withdrawn
CHU Sao Joao Porto Portugal Recruiting
Samsung Medical Center Seoul South Korea Recruiting
Seoul ASAN Medical Center Seoul South Korea Withdrawn
Yonsei University Severance Hospital Seoul South Korea Recruiting
Hospital De Bellvitge Barcelona Spain Recruiting
Hospital General De Asturias Oviedo Spain Recruiting

More Boston Scientific Corporation trials in Belgium

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04032470 on ClinicalTrials.gov ↗ ← All trials in Belgium